Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.

Press Releases

Emmes Honored for Workplace Excellence
Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.
Regulatory update: PRRC
New Medical Device Guidance on Article 15 of the MDR and IVDR regarding person responsible for regulatory compliance
Emmes-Supported Study Results in the First Pediatric Drug Labeling Change for 2019
Emmes today announced that it provided the data management support for a study, funded by the National Institutes of Health (NIH) and approved by the Food and Drug Administration (FDA), to safely use Acyclovir to treat infants infected with the Herpes Simplex Virus. Acyclovir, known by the brand name Zovirax, now includes recommended usage and dosage for newborns and infants up to three months of age on its label.
Neox's work recognized in Athero Review
Congrats to the Neox team and their work, which was recognized in a recent publication
Behrman Capital Makes Significant Investment in Emmes
Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.
The Washington Business Journal Recognizes Emmes in Two "Top Company" Lists 10/30/2018
The Washington Business Journal Recognizes Emmes in Two "Top Company" Lists
The Emmes Corporation today announced that it was named one of the largest women-owned businesses in the Washington metropolitan area by the Washington Business Journal. Emmes was ranked the sixth largest women-owned business in the Washington region, up from number seven last year. Last month, Emmes was named as one of the top 100 largest private companies in the area. Emmes ranked 83rd, up from 95th the previous year, in the Washington Business Journal’s annual list.
This is to inform you about how your personal data is processed by NEOX s.r.o. These principles describe how your personal data is obtained and processed. At the same time, please be assured that any and all personal data processed is considered as strictly confidential by NEOX s.r.o. and is handled in compliance with applicable legal regulations. Personal data is under the control and protection of NEOX s.r.o., and NEOX s.r.o. has established mechanisms to ensure an adequate protection of processed personal data against its misuse.
Traumatic Brain Injury Research by Emmes Corporation, LDS Hospital, Lovelace Biomedical Environmental Research Institute, and U.S. Army Tests Use of Hyperbaric Oxygen as a Potential Treatment Option
The Emmes Corporation today announced that scientists and health professionals from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have completed a multi-year clinical trial testing hyperbaric oxygen as an intervention for U.S. military service members who have suffered mild traumatic brain injuries with persistent symptoms.
Emmes Launches New Internship Program with an Egyptian Children's Cancer Hospital
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
Emmes and IDx Partner Using Artificial Intelligence to Detect Diabetic Retinopathy in Primary Care
The Emmes Corporation today announced the completion of a pivotal clinical trial for a new product developed by IDx that could help in detecting diabetic retinopathy, the leading cause of blindness in the United States. IDx-DR is a fully autonomous AI-based diagnostic system that analyzes images of the retina for signs of diabetic retinopathy, providing instructions for follow-up care based on the level of disease detected. IDx-DR has been granted expedited review by the Food and Drug Administration.
Seven Emmes Employees Recognized in Lancet Study Comparing Two Opioid Treatments
The Emmes Corporation today announced its participation in a three-year study testing the results of two different opioid treatment medications. The research, published in one of the world’s oldest and best known medical journals, concluded that for those able to begin treatment, both drugs are nearly equal in their safety and effectiveness. The National Institute on Drug Abuse (NIDA) funded the research. In addition to providing data management and statistical support, Emmes served as the clinical coordinating center. This involved protocol development, pharmacovigilance, quality assurance, safety monitoring and regulatory support. The clinical trial occurred between 2014 to 2017 at eight community treatment programs across the U.S. A total of 570 patients participated, with each group followed for a 24-week period.
New Research Links Umbilical Cord Blood to Motor Function Improvement in Children with Cerebral Palsy
The Emmes Corporation today announced its statistical and data management support of a clinical trial that offers new hope for children with cerebral palsy (CP). Stephen Wease and Dr. Beth Blackwell joined a team of prominent researchers from Duke University Medical Center to test whether umbilical cord blood would improve motor skills function in children suffering from the disorder. According to Wease, Emmes project leader, “The phase II trial showed promising results, and we’re eager for the next phases of research to further our understanding of this encouraging new mechanism for treating children with CP.”